Maxwell Biomedical
Maxwell Biomedical is a science-driven, innovative medical technology company dedicated to developing long-term, non-destructive solutions for atrial fibrillation (AFib) and heart failure with preserved ejection fraction (HFpEF). The company focuses on advancing cardiac care through cutting-edge research and innovative devices, including the groundbreaking Spatial Resynchronization Therapy (SRT) system, which aims to restore and maintain sinus rhythm, improve heart function, and reduce symptoms and hospitalizations in patients with AFib and HFpEF. Maxwell Biomedical's mission is to transform patient outcomes by providing safe, effective, and minimally invasive therapies that address the electromechanical causes of these heart conditions.
Industries
Nr. of Employees
small (1-50)
Maxwell Biomedical
Products
Implantable atrial resynchronization therapy system (non-destructive atrial pacing device)
A miniature implantable system that continuously senses atrial rhythm, delivers imperceptible, critically timed low-energy multi-site pacing to terminate atrial fibrillation and restore biatrial synchrony, and transmits monitoring data to the cloud for clinician review.
Implantable atrial resynchronization therapy system (non-destructive atrial pacing device)
A miniature implantable system that continuously senses atrial rhythm, delivers imperceptible, critically timed low-energy multi-site pacing to terminate atrial fibrillation and restore biatrial synchrony, and transmits monitoring data to the cloud for clinician review.
Services
Cloud-based upload and physician-accessible monitoring of continuous device ECG recordings to support remote management of atrial fibrillation and heart failure patients.
Cloud-based upload and physician-accessible monitoring of continuous device ECG recordings to support remote management of atrial fibrillation and heart failure patients.
Expertise Areas
- Clinical trial management for implantable cardiac devices
- Cardiac electrophysiology device development
- Leadless and multisite pacing systems
- Wireless power transfer for implantable devices
Key Technologies
- Wireless power transfer (WPT)
- Leadless pacemaker hardware
- Low-energy multi-pulse pacing/defibrillation
- Closed-loop arrhythmia detection and therapy algorithms
News & Updates
Maxwell Biomedical Expands Clinical Study for SRT in AF and HFpEF Patients
The company is expanding its clinical study to validate Spatial Resynchronization Therapy (SRT) for patients with AF and HFpEF, aiming to improve outcomes and broaden access.
Acceptance of Abstracts at Heart Rhythm Society 2023
Maxwell Biomedical announced the acceptance of two abstracts for presentation at the HRS 2023 Annual Conference, highlighting their innovative therapies.
Acquisition of Cardialen’s Assets
Maxwell Biomedical completed the acquisition of Cardialen’s assets, including MultiPulse™ Therapy, to enhance its product portfolio for AFib and VT treatment.
Proof-of-Concept Human Study Enrollment for SRT
The company successfully completed enrollment in its first-in-human clinical trial demonstrating the ability of Spatial Resynchronization Therapy to terminate AFib and restore sinus rhythm.
FDA Approval for Clinical Trial of Low-Energy AFib Treatment
Cardialen received FDA approval to conduct a clinical trial of its low-energy MultiPulse™ Therapy for atrial fibrillation.
Physiologic Computer Modeling of Atrial Fibrillation
A realistic computer simulation model to test and develop treatment strategies for AFib.
Maxwell Biomedical Expands Clinical Study for SRT in AF and HFpEF Patients
The company is expanding its clinical study to validate Spatial Resynchronization Therapy (SRT) for patients with AF and HFpEF, aiming to improve outcomes and broaden access.
Acceptance of Abstracts at Heart Rhythm Society 2023
Maxwell Biomedical announced the acceptance of two abstracts for presentation at the HRS 2023 Annual Conference, highlighting their innovative therapies.
Acquisition of Cardialen’s Assets
Maxwell Biomedical completed the acquisition of Cardialen’s assets, including MultiPulse™ Therapy, to enhance its product portfolio for AFib and VT treatment.
Proof-of-Concept Human Study Enrollment for SRT
The company successfully completed enrollment in its first-in-human clinical trial demonstrating the ability of Spatial Resynchronization Therapy to terminate AFib and restore sinus rhythm.
FDA Approval for Clinical Trial of Low-Energy AFib Treatment
Cardialen received FDA approval to conduct a clinical trial of its low-energy MultiPulse™ Therapy for atrial fibrillation.
Physiologic Computer Modeling of Atrial Fibrillation
A realistic computer simulation model to test and develop treatment strategies for AFib.